The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...
– New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to ...
Both features are key for security and B2B e-commerce, particularly as Microsoft works to integrate better extranet and cross-company authentication features in a Windows Server update due out in 2005 ...
Clinical-stage biotechnology company Immunic, Inc. (NASDAQ:IMUX) is focused on developing an orally administered, small-molecule therapy for treating multiple sclerosis (MS). In our last article, we ...
September and October 2025 have proven busy for multiple sclerosis (MS) professionals, as many gathered at three major conferences to discuss trials in the indication that could alter the current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results